FDA Can Expand Access To Experimental Drugs, Without Compromising Trials
Executive Summary
FDA would be able to maintain the integrity of rigorous clinical trials and permit increased access to experimental drugs through the use of better science, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb
You may also be interested in...
Outcome Of Abigail Alliance Case May Be Moot Due To Marketplace Issues
Regardless of whether a federal appeals court determines that patients have a fundamental right to experimental therapy, it appears a host of potential problems in the marketplace will stymie increased access to such therapies in practice
Outcome Of Abigail Alliance Case May Be Moot Due To Marketplace Issues
Regardless of whether a federal appeals court determines that patients have a fundamental right to experimental therapy, it appears a host of potential problems in the marketplace will stymie increased access to such therapies in practice
Lawsuit On Sale Of Investigational Drugs Divides Oncology Community
Allowing patients to buy investigational drugs would undermine FDA's clinical trial system, medical groups contend in a pair of amicus briefs seeking to reverse an appeals court ruling